HD Melphalan and SCT in Patients With IGDD or LCDD
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy before a stem cell transplant stops the growth of cancer cells
by stopping them from dividing or killing them. Giving colony-stimulating factors, such as
G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the
blood so they can be collected and stored. Chemotherapy is then given to prepare the bone
marrow for the stem cell transplant. The stem cells are then returned to the patient to
replace the blood-forming cells that were destroyed by the chemotherapy.
PURPOSE: This phase II trial is studying the side effects of high-dose melphalan given
together with stem cell transplant and to see how well it works in treating patients with
immunoglobulin deposition disease or light-chain deposition disease.